Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

<p>DEG Table for R vs NR (mRNAseq)</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Gregory L. Beatty (15087193) (author)
Diğer Yazarlar:	Devora Delman (15129986) (author), Jiayi Yu (16743347) (author), Mingen Liu (16743350) (author), Joey H. Li (15129989) (author), Liti Zhang (16743353) (author), Jae W. Lee (16743356) (author), Renee B. Chang (15129983) (author), Nathan Bahary (16743359) (author), Eugene P. Kennedy (16743362) (author), Andrea Wang-Gillam (15049923) (author), Gabriela R. Rossi (16743365) (author), Ignacio Garrido-Laguna (15131889) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Therapeutic Research and Development Chemotherapy Gastrointestinal Cancers Pancreatic cancer Translational Research
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Yazar:: Gregory L. Beatty (15087193)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
Yazar:: Jiachun Su (16990970)
Baskı/Yayın Bilgisi: (2025)

Image 9_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Image 8_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Image 6_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Image 7_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Image 4_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Image 5_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Image 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Image 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Image 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Table 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Table 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Table 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
Yazar:: Xiangjun Wang (2522917)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Yazar:: Erika Y. Faraoni (14844897)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Yazar:: Erika Y. Faraoni (14844897)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Yazar:: Erika Y. Faraoni (14844897)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Yazar:: Yan Zhou (15053225)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Yazar:: Fang Wei (15057172)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S2 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Yazar:: Fang Wei (15057172)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S3 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Yazar:: Fang Wei (15057172)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S4 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Yazar:: Fang Wei (15057172)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S5 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Yazar:: Fang Wei (15057172)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S6 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Yazar:: Fang Wei (15057172)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S7 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Yazar:: Fang Wei (15057172)
Baskı/Yayın Bilgisi: (2025)

Supplementary Movie S8 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Yazar:: Fang Wei (15057172)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Yazar:: Arun Kanakkanthara (14937731)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Yazar:: Arun Kanakkanthara (14937731)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Yazar:: Elizabeth R. Tucker (15053624)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Yazar:: Elizabeth R. Tucker (15053624)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Yazar:: Elizabeth R. Tucker (15053624)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Yazar:: Elizabeth R. Tucker (15053624)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Yazar:: Elizabeth R. Tucker (15053624)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Yazar:: Elizabeth R. Tucker (15053624)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Comprehensive DNA Methylation Analysis Indicates That Pancreatic Intraepithelial Neoplasia Lesions Are Acinar-Derived and Epigenetically Primed for Carcinogenesis
Yazar:: Emily K.W. Lo (15618846)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_pp4vud8t1rqib9a7a3tmq3t21l